Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Non-Small-Cell Lung 6Neoplasm, Residual 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1

Interventions

Rituximab 161Cyclophosphamide 142fludarabine phosphate 89Peripheral Blood Stem Cell Transplantation 81Filgrastim 59Mycophenolic Acid 58Whole-Body Irradiation 53Cyclosporine 53Radiotherapy 52Lenalidomide 47Busulfan 45Tacrolimus 44Etoposide 43Antilymphocyte Serum 41Melphalan 37Methotrexate 31fludarabine 30Bortezomib 30Prednisone 28Bendamustine Hydrochloride 28Cytarabine 24Cord Blood Stem Cell Transplantation 23obinutuzumab 22Vincristine 22Methylprednisolone 21Flow Cytometry 21ibrutinib 19venetoclax 17sargramostim 17Granulocyte Colony-Stimulating Factor 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Maintenance × Clear all
NCT04542824 2026-05-05

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07372365 2026-01-28

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
23 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡